Zanubrutinib Approved for Relapsed/Refractory Marginal Zone Lymphoma

The FDA has granted accelerated approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. "Marginal zone lymphoma is rare and heterogeneous, and it has been difficult to define optimal therapeutic strategies," wrote Stephen Opat, FRACP, FRCPA, MBBS, Director of Clinical Hematology at Monash Health in Australia, and colleagues, in their publication of the initial results...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.